Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of “Moderate Buy” by Analysts

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been given a consensus recommendation of “Moderate Buy” by the seventeen brokerages that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, thirteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $104.4545.

GPCR has been the topic of several analyst reports. Morgan Stanley upped their target price on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Jefferies Financial Group set a $125.00 price objective on Structure Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 11th. Citigroup reissued an “outperform” rating on shares of Structure Therapeutics in a report on Friday, December 12th. Stifel Nicolaus boosted their price target on Structure Therapeutics from $50.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Thursday, January 22nd.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $72.04 on Friday. Structure Therapeutics has a 1 year low of $13.22 and a 1 year high of $94.90. The firm’s 50-day moving average is $74.30 and its 200 day moving average is $42.69. The stock has a market cap of $4.37 billion, a price-to-earnings ratio of -59.05 and a beta of -2.06.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. grew its position in Structure Therapeutics by 7.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock worth $32,939,000 after purchasing an additional 106,389 shares during the period. Casdin Capital LLC grew its holdings in shares of Structure Therapeutics by 26.9% in the third quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock worth $43,540,000 after acquiring an additional 330,000 shares during the period. Principal Financial Group Inc. grew its holdings in shares of Structure Therapeutics by 63.1% in the fourth quarter. Principal Financial Group Inc. now owns 1,284,210 shares of the company’s stock worth $89,317,000 after acquiring an additional 496,726 shares during the period. Millennium Management LLC increased its position in Structure Therapeutics by 4.5% during the third quarter. Millennium Management LLC now owns 1,274,551 shares of the company’s stock valued at $35,687,000 after acquiring an additional 54,496 shares during the last quarter. Finally, Orbimed Advisors LLC lifted its holdings in Structure Therapeutics by 49.5% in the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock valued at $24,873,000 after acquiring an additional 397,272 shares during the period. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.